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Abstract
The proportional hazards (PH), proportional odds (PO) and accelerated failure
time (AFT) models have been widely used in different applications of survival analysis.
Despite their popularity, these models are not suitable to handle lifetime data with
crossing survival curves. In 2005, Yang and Prentice proposed a semiparametric two-
sample strategy (YP model), including the PH and PO frameworks as particular cases,
to deal with this type of data. Assuming a general regression setting, the present paper
proposes an unified approach to fit the YP model by employing Bernstein polynomi-
als to manage the baseline hazard and odds under both the frequentist and Bayesian
frameworks. The use of the Bernstein polynomials has some advantages: it allows for
uniform approximation of the baseline distribution, it leads to closed-form expressions
for all baseline functions, it simplifies the inference procedure, and the presence of a
continuous survival function allows a more accurate estimation of the crossing survival
time. Extensive simulation studies are carried out to evaluate the behavior of the mod-
els. The analysis of a clinical trial data set, related to non-small-cell lung cancer, is also
developed as an illustration. Our findings indicate that assuming the usual PH model,
ignoring the existing crossing survival feature in the real data, is a serious mistake with
implications for those patients in the initial stage of treatment.
Keywords: Bernstein polynomials; Survival analysis; Proportional hazards; Propor-
tional odds; Yang and Prentice model.
1 Introduction
Proportional hazards (PH) models (Cox, 1972) have played a central role in many appli-
cations related to survival analysis. This class of models provides a flexible framework for
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time-to-event data and allows an easy interpretation of parameters, from the practical point
of view. The main assumption of the PH models is the proportionality of the hazards ra-
tios over time. When such assumption is not verified for the data, some alternatives are
available, such as the proportional odds (PO) (Bennett, 1983) and the accelerated failure
time (AFT) (Kalbfleisch and Prentice, 2002) models. However, none of these alternatives
can accommodate survival data with crossing survival curves.
Crossing survival curves may arise due to several reasons. According to Diao et al. (2013),
this can happen in clinical trials where a particular aggressive treatment (e.g. surgery) can
have adverse effects at the beginning, but it may show beneficial results in the long run.
Furthermore, as discussed in Breslow et al. (1984), crossing survival curves may also occur
(see Figure 1) when a treatment has an early quick effect and it becomes similar or worse
than the placebo treatment after a time period. One example of this type of situation can
be observed in the IRESSA Pan-Asia Study (IPASS). The IPASS clinical trial is a phase 3,
open-label study, conducted with the primary objective of showing the noninferiority of the
drug gefitinib compared to the option carboplatin-paclitaxelin as a first-line therapy for the
intention-to-treat population patients with lung cancer (Mok et al., 2009).
The results of the IPASS clinical trial were firstly analyzed by Mok et al. (2009), who
stated the superiority of gefitinib over carboplatin/paclitaxel. Gefitinib was approved in
the U.S. in 2015 as a first-line therapy by the Food and Drug Administration (FDA), and
nowadays is marketed in over 90 countries. Nevertheless, the superiority of gefitinib over
carboplatin/paclitaxel must be interpreted with caution, since the PH assumption is clearly
violated for this data set, and any statistical analysis based on the PH model, as in Mok
et al. (2009), is not appropriate in this case. In addition, the inspection of the Kaplan-
Meyer estimates of the survival curves provided in Mok et al. (2009) indicates that, although
gefitinib appears to have a superior performance over carboplatin/paclitaxel in the long run,
the same does not seem to be true at earlier stages of treatment. In this fashion, a model
capable of detecting treatment differences at initial and final periods of follow up time would
be desired. Furthermore, from the practical point of view, in order to increase patients’
survival probabilities it is extremely important to take into account the time at which the
treatments invert their effectiveness.
Several approaches have been proposed in the literature to handle lifetime data with
crossing survival curves. The most popular are the ones based on time-varying regression
coefficients. However, this type of models has some drawbacks such as a larger number
of parameters, implying in higher model complexity, and results harder to interpret. As
an interesting alternative, Yang and Prentice (2005) proposed a semiparametric two-sample
model (YP model hereafter) that includes the PH and PO frameworks as particular cases. In
their model the baseline hazard function is not specified, and a pair of short and long-term
hazards ratio parameters is included in the model to accommodate the feature of survival
curves intersecting each other. A pseudo maximum likelihood approach is considered to
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estimate the parameters. Consistency and asymptotic normality of the estimators were
evaluated in their work. Yang and Prentice (2011) extended the estimation procedure in Yang
and Prentice (2005) to separate and simultaneous inference on the hazards ratio function
itself. The authors prove the consistency and asymptotic normality of estimates at a fixed
time point. Yang et al. (2012) proposed two omnibus tests to verify how appropriate is the
YP model for the data. The first test is based on the martingale residuals and the second
one accounts for the contrast between the nonparametric and model-based estimators for
the survival function. Diao et al. (2013) extended the two-sample YP model to a general
regression setting with possibly time-dependent covariates. They have also developed an
efficient likelihood-based estimation procedure and demonstrated the consistency, asymptotic
normality and efficiency of the estimators. The YP model is also extended in Tong et al.
(2007) to accommodate current status survival data. Zhang et al. (2017) considers the YP
model to fit case II interval-censored data.
In the past years, the Bernstein polynomials (BP) have gained visibility rising as an
instrument for the statistical analyses in different applications. A thorough presentation of
BP and its main mathematical aspects can be found in Lorentz (2012). The use of BP for
density estimation is a very common topic in the literature. This idea was proposed in Vitale
(1975) and later explored in Petrone (1999), Babu et al. (2002) and Choudhuri et al. (2004).
Some authors have also considered the BP as an strategy to enhance regression modeling
results; two interesting examples are Tenbusch (1997) and Chang et al. (2007). There are
few studies using the BP to model survival data. A quick online search combining the key-
words “survival analysis" and “Bernstein Polynomials" currently returns a short list of works.
One of them is Chang et al. (2005), which considers the Bayesian framework to estimate
the hazard function by assuming a Beta process prior and an homogeneous population due
to the absence of covariates. In this reference, the polynomial degree is a random quantity
that should be estimated. Another reference is Osman and Ghosh (2012), which is focused
on the estimation of the hazard function in the context of crossing survival curves. The
paper proposes a likelihood maximization procedure and considers the polynomial degree as
a known quantity. A third reference is Chen et al. (2014), which investigates an accelerated
hazard model incorporating the Dirichlet process and assuming a random polynomial de-
gree. Their Bayesian analysis proposes a transformed Bernstein polynomial prior centered
at standard parametric families (e.g. Weibull). More recently, Zhou and Hanson (2017)
presented an unified approach to handle arbitrarily censored spatial survival data in three
semiparametric contexts: PH, PO and AFT. Baseline survival is modeled with the trans-
formed Bernstein polynomial prior. This is essentially a Dirichlet process prior, assumed
for the polynomials coefficients, having a parametric baseline distribution representing the
center of the unknown survival function. Zhou et al. (2017) considers semiparametric trans-
formation models for interval-censored data. In their approach, Bernstein polynomials are
applied to approximate the unknown baseline cumulative hazard function.
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The present paper takes advantage of the flexibility brought by the Bernstein polynomials
as a representation for the hazard function or the odds function in the YP model. The BP
modeling provides a continuous survival function and this feature allows a more accurate
estimation of the time point where the curves are crossing. Note that, this accuracy is
compromised when working with a stepwise survival curve, which is currently considered
in Yang and Prentice (2005) and other references. A comprehensive simulation study is
developed here to show that the BP modeling is in fact a good option for the analysis, being
able to correctly capture the true shape of the survival function and estimate the regression
coefficients, and the crossing survival times as well, with small bias. Our proposal configures
a more appropriate model to handle the aforementioned IPASS data where the inversion
of treatment performances is clear. In order to illustrate the gain in terms of analysis, we
explore a reconstructed version of this data set provided in Argyropoulos and Unruh (2015).
Another interesting aspect investigated in this paper is related to the effects of more
than one covariate. This has been previously mentioned in the literature, but never properly
explored through simulation studies. According to Yang and Prentice (2005), it is reasonable
to assume in some applications that a subset of the covariates has the same coefficients for
both short and long-term hazard ratios. In other words, the impact of those covariates
is constant along the time and does not have a key contribution to explain the crossing
behavior of the curves. As an example, for some diseases the gender of the patients may
not be regarded as a factor modifying the decay speed of the survival curves, corresponding
to treatment and control groups, between the short and long term periods. In this case,
it would be more natural to consider the variable gender having the same effect on both
hazards ratios. This assumption has important implications for the analysis, since it reduces
the model complexity and the computational cost. The larger the subset of covariates with
the same impact on both ratios, the more parsimonious is the model.
The main contributions of this paper are:
• It proposes novel semiparametric approaches to model right-censored lifetime data with
crossing survival curves. The main motivation is the YP model, which is improved here
by using the BP to allow a continuous hazard or odds function.
• To the best of our knowledge, all semiparametric frameworks proposed in the literature
to extend the YP model, and the original YP model itself, determine an increasing step
function representation for the cumulative hazard or the odds function. Smoothness
can be obtained when the BP are employed to model those baseline functions.
• The methodologies are investigated under the frequentist and Bayesian frameworks for
a broaden presentation of models to be considered by all audiences in statistics.
• A comprehensive simulation study is developed. This involves more than one covariate
to explain the long and short-term hazard ratios. The reader should note that only
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the single covariate scenario is investigated in important references such as Diao et al.
(2013) and Nieto-Barajas (2014).
• The Bernstein polynomials are used to model either the baseline hazard or the baseline
odds of the YP model. All previous works are focused in only one of them; for example,
Yang and Prentice (2005) and Nieto-Barajas (2014) model the odds function and Diao
et al. (2013) considers the hazard function.
• The paper evaluates both strategies assuming all or only a subset of the covariates
with distinct coefficients affecting the short and long-term hazard rations. The subset
scenario sharing the same coefficients for these terms is only mentioned in Yang and
Prentice (2005) and has never been explored through simulations.
This paper is organized as follows. The proposed versions of the YP models assuming
the BP to represent the baseline hazard or the odds are described in Section 2. This section
also introduces notations and describes the scenarios with and without a subset of covariates
having the same impact over the short and long-term ratios. A simulation study is conducted
in Section 3 to evaluate the performance of the models under the two-sample scenario and
the general regression setting. In Section 4, the analysis of the reconstructed IPASS data is
developed to show the advantages of the proposed model. Finally, Section 5 discusses the
main conclusions and final remarks.
2 Model Formulations
This section presents the details related to the specification of four different versions of the
YP model for crossing survival curves. The distinctions among the models are related to:
(i) using the BP to handle the hazard function or the odds function and (ii) setting different
short and long-term hazards ratios coefficients for all covariates or assuming a subset of
covariates having the same coefficients for both ratios.
2.1 Yang and Prentice Model
Let T be a nonnegative random variable representing the time until the occurrence of an
event of interest. In order to accommodate survival data with crossing survival curves, Yang
and Prentice (2005) proposed the following model
S(t|Θ, z) =
[
1 +
λ
θ
R0(t)
]−θ
, (1)
where z = (z1, . . . , zq) is a set of explanatory variables, λ = exp{zψ} and θ = exp{zφ},
ψ> = (ψ1, . . . , ψq) and φ> = (φ1, . . . , φq) are vectors of regression coefficients, not in-
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cluding intercepts, Θ = (ψ,φ), and R0(t) is a monotonic increasing function satisfying
limt→0R0(t) = 0 and limt→∞R0(t) =∞.
The hazard function associated with (1) takes the form
h(t|Θ, z) = λθ R
′
0(t)
λ+ θR0(t)
, where R′0(t) =
d
dt
R0(t). (2)
If z = 0, then (1) reduces to
S0(t) = S(t|Θ,0) = 1
1 +R0(t)
, (3)
which is referred to as the baseline survival function. Naturally, we can write F0(t) =
1 − S0(t). In addition, this result and (3) imply that R0(t) = F0(t)/S0(t), therefore, R0(t)
corresponds to the baseline odds function. As a consequence, R′0(t) = h0(t)/S0(t), where
h0(t) = − ddt lnS0(t) is the baseline hazard function.
The hazard function in (2) can be rewritten in terms of the baseline functions h0(t), F0(t)
and S0(t) as follows
h(t|Θ, z) = λθ
λF0(t) + θS0(t)
h0(t). (4)
From expression (4), one can easily see that
lim
t→0
h(t|Θ, z)
h(t|Θ,0) = exp{zψ} = λ,
lim
t→∞
h(t|Θ, z)
h(t|Θ,0) = exp{zφ} = θ.
Thus, the quantities λ and θ can be interpreted as the short and long-term hazards ratios,
respectively. In line with this notation, ψ and φ are regarded as the short and long-term
regression coefficients. Another attractive feature of the YP model is the fact that it includes
the PH (when ψ = φ) and PO (when φ = 0) models as particular cases. Moreover, it can be
shown that crossing survival curves occur when ψjφj < 0, i.e. when ψj and φj have opposite
signs for any j = 1, . . . , q.
According to Yang and Prentice (2005), an alternative formulation of their model can
be obtained by assuming that the effects of some covariates do not change through time.
Although appealing from the practical point of view in many real situations, as far as we
known, such alternative formulation has not been addressed in the literature until now. The
alternative formulation of the YP model can be obtained as follows. Denote by z∗ = (z,x)
a 1× q∗ vector of covariates, with q∗ = q + p, where z is a 1× q vector incorporating those
explanatory variables whose effects are expected to change between the short and long-term
periods, and x is a 1×p vector including those covariates whose effects are expected to remain
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constant over time. Let ψ∗ = (ψ,β) and φ∗ = (φ,β), where ψ and φ are q × 1 vectors
containing the short and long-term regressions coefficients associated with z, respectively,
and β is a p × 1 vector of constant-time regression coefficients associated with x. Then,
replacing Θ and z by Θ∗ = (ψ∗,φ∗) ≡ (ψ,φ,β) and z∗ in the expressions presented above,
it is straightforward to show that the new hazard and survival functions associated with the
alternative formulation of the YP model are expressed, respectively, as
h(t|Θ∗, z∗) = h(t|Θ, z)exβ, (5)
S(t|Θ∗, z∗) = S(t|Θ, z)exβ ;
where h(t|Θ, z) and S(t|Θ, z) were previously defined; see the expressions in (2), (4) and
(1). Thus, given z, the proportional hazards assumption holds for (5).
In order to fit the YP model, one can either focus on modeling the baseline hazard or
the baseline odds function. This task has been traditionally done by means of step functions
with jumps defined by the observed failure times (see, for instance, Yang and Prentice, 2005;
Tong et al., 2007; Diao et al., 2013; Nieto-Barajas, 2014). One drawback of these approaches
is the fact that the resulting survival functions are also step functions, with jumps defined by
the observed failure times. From the practical point of view, a continuous survival function
would be convenient, since it allows a more accurate identification of the time at which the
survival curves intersect each other. As it will be demonstrated ahead, this issue can be
easily addressed by using Bernstein polynomials, which are briefly described next.
2.2 Bernstein Polynomials in Survival Analysis
Let C(·) be a continuous function on the interval (0, τ ]. The Bernstein polynomial of order
m evaluated in t ∈ (0, τ ], with base Bm = (B0,m, B1,m, . . . , Bm,m), and coefficients bm =
(b0,m, b1,m, . . . , bm,m), intended to approximate a given function C(·), is defined by
Bm(t;C) =
m∑
k=0
bk,m Bk,m(t), (6)
where Bk,m =
(
m
k
)
(t/τ)k(1−t/τ)m−k and bk,m = C(kτ/m), for k = 0, 1, . . . ,m. The literature
related to the BP shows that Bm(·;C) → C(·) uniformly on (0, τ ] as m → ∞. Details can
be found in Lorentz (2012) and references therein.
The first derivative of Bm(t;C), denoted by bm(t;C), can be written as
bm(t;C) =
∑m
k=1
[
C
(
k
m
τ
)− C (k−1
m
τ
)] fB(t/τ |k,m−k+1)
τ
, (7)
where fB is the density of the beta distribution evaluated at t/τ and having shape parameters
k and m − k + 1. The literature also shows that bm(·;C) → c(·) as m → ∞, uniformly on
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(0, τ ], where c(t) = dC(t)/dt.
According to Osman and Ghosh (2012) the hazard function can be modeled as follows
h(t|γ) =
m∑
k=1
γk gk,m(t) = γ gm(t), for t ≥ 0; (8)
where γ = (γ1, . . . , γm) is the vector of unknown coefficients satisfying γk ≥ 0, for k =
1, . . .m. In addition, gm(t) = (g1,m(t), . . . , gm,m(t))> is the vector of baseline functions
evaluated at the time point t. In this case, gk,m(t) ≥ 0 and
∫∞
0
gk,m(u)du < ∞ for all
k ≤ m. This result is connected with the one expressed in (7), therefore, we can identify
gk,m(t) = fB(t/τ |k,m− k + 1)/τ and γk = C
(
k
m
τ
)− C (k−1
m
τ
)
.
The cumulative hazard function is given by
H(t|γ) =
∫ t
0
m∑
k=1
γk gk,m(u)du =
m∑
k=1
γk
∫ t
0
gk,m(u)du
=
m∑
k=1
γk Gk,m(t) = γGm(t), for t ≥ 0. (9)
Here, Gk,m(t) = FB(t/τ |k,m − k + 1), for k = 1, . . . ,m, and FB represents the cumulative
distribution function (c.d.f.) of the Beta(k, m− k + 1) evaluated at t/τ . The monotonicity
of H(t|γ) is ensured by the restrictions: γk ≥ 0 and gk,m(t) ≥ 0, for t > 0 and k = 1, . . . ,m.
Formally, for the context of survival analysis, one must set τ <∞ such that τ = inf{t :
S(t) = 0}. However, the specification in (9) does not satisfy H(τ |γ) = ∞. It is necessary
to apply a tail adjustment to correct this issue. Osman and Ghosh (2012) suggest choosing
τˆ = max{t1, . . . , tn}, where ti is the i-th observed time point, and then assuming a con-
stant hazard function for t > τˆ , since there is no data information about the failure time
distribution in this region. The hazard function can be written as follows
h∗(t|γ) =
{
h(t|γ), if 0 ≤ t < τˆ ,
m γm/τˆ , if t ≥ τˆ .
The corresponding cumulative hazard function is
H∗(t|γ) =
{
H(t|γ), if 0 ≤ t < τˆ ,
H(t|γ) +m (t− τˆ) γm/τˆ , if t ≥ τˆ .
It can be shown that
∫∞
0
h∗(t|γm,m) dt = ∞, therefore, the mentioned tail adjustment
determines a valid hazard function. The indicated τˆ ensures that all observations impacting
the likelihood are handled by the BP, thus the properties of the survival model considered
for the application are unaffected. Note that, as the sample size increases (n→∞) the value
τˆ → τ = inf{t > 0 : S(t) = 0} in probability.
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Since R0(t) behaves like H0(t), it is reasonable to consider the same structure adopted
for H0(t) to model the baseline odds R0(t). In line with this idea, we set
R′0(t|ξ) =
m∑
k=1
ξk gk,m(t) and R0(t|ξ) =
m∑
k=1
ξk Gk,m(t), (10)
where ξm = (ξ1,m, . . . , ξm,m) is the vector of unknown coefficients, with ξk,m ≥ 0 for k =
1, . . . ,m. The notation ξm is introduced to make distinction with respect to γm specified
for the hazard function case. The definitions of gk,m(t) and Gk,m(t) did not change here.
2.3 Proposed Models
We propose to model both h0(·) and R0(·) using the Bernstein polynomials. Two versions
are considered for the YP model. The first one is the original formulation presented in the
literature, which assumes different effects over the short and long-term hazards ratios for all
covariates; hereafter this version is referred to as “original YP model”. The second option
assumes that the effect over the short and long-term ratios is the same for a subset of the
covariates; this version will be denoted as “alternative YP model”. The four configurations
of models to be explored are indicated in Table 1.
Table 1: Model specifications being explored in the present paper.
YP version Model Parameters BP for
original M1 Θ1 = (ψ,φ,γ) h0(·)
M2 Θ2 = (ψ,φ, ξ) R0(·)
alternative M∗1 Θ
∗
1 = (ψ,φ,β,γ) h0(·)
M∗2 Θ
∗
2 = (ψ,φ,β, ξ) R0(·)
In M1 and M∗1 , the hazard function takes the form in (4) and the BP representation in
(8) is assumed for h0(t). As a consequence, the baseline cumulative hazard H0(t) is given in
(9). Regarding the baseline survival function, recall that S0(t) = exp{−H0(t)}. The models
M2 and M∗2 use the second formulation of the hazard function presented in (2). Here, the
BP representations in (10) are considered for the baseline odds function and its derivative.
Consider a random sample of size n of independent elements and denote by Ti and Ci,
respectively, the failure and censoring times. Recall the previous notation and let zi and
xi, for i = 1, · · · , n, be two vectors of explanatory variables. Assume that the censoring
mechanism is non-informative. In addition, assume the failure times are right-censored so
that Yi = min{Ti, Ci} establishes the observed time for subject i. Let δi = I{Ti≤Ci} be the
failure indicator function. Further denote D∗ = {(yi, δi, zi,xi), i = 1, · · · , n} as the full
set of observed data. Then, under the alternative formulation of the YP model, a general
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expression for the likelihood function can be written as
L(Θ∗r|D∗) =
n∏
i=1
[
h(ti|Θr, zi)exiβ
]δi [
1 +
λi
θi
R0(ti|κr)
]−θiexiβ
, (11)
where Θ∗r = (ψ,φ,β,κr), r = 1 or 2, denotes the set of parameters to be estimated.
We set κ1 = γ or κ2 = ξ, depending on choice of the baseline (hazard or odds) func-
tion to be modeled by the Bernstein polynomials. Specifically, the likelihood function
associated with model M∗1 is obtained by setting: h0(ti) = h0(ti|γ) =
∑m
k=1 γk,mgk,m(t),
H0(ti) = H0(ti|γ) =
∑m
k=1 γk,mGk,m(t), S0(ti|γ) = exp{−H0(ti|γ)}, F0(ti|γ) = 1 − S0(ti|γ)
and R0(ti|γ) = F0(ti|γ)/S0(ti|γ). For Model M∗2 , the likelihood function is configured with:
R′0(ti) = R
′
0(ti|ξ) =
∑m
k=1 ξk,mgk,m(t) and R0(ti) = R0(ti|ξ) =
∑m
k=1 ξk,mGk,m(t).
If no covariates are expected to have their effects constant over time, then xi = 0 and
expression (11) reduces to
L(Θr|D) =
n∏
i=1
h(ti|Θr, zi)δi
[
1 +
λi
θi
R0(ti|κr)
]−θi
, (12)
where D = {(yi, δi, zi), i = 1, · · · , n}, Θr = (ψ,φ,κr) with r = 1 or 2. In this case, we have
the general expression for the likelihood function associated with the original formulation of
the YP model.
The closed form for the likelihood functions given in (11) and (12) allows us to easily
employ likelihood-based methods to estimate parameters and related quantities. In order to
determine the maximum likelihood (ML) estimates, one can apply direct maximization of
the log-likelihood function l(Θ) = logL (Θ;D) by using the quasi-Newton BFGS method
available in standard statistical softwares such as R (R Core Team, 2019) and SAS (www.
sas.com).
It is worth noting that, although the observed Fisher information matrix, provided by the
BFGS method, can be used to obtain point and interval estimates, it is not straightforward
to determine an interval estimate for the crossing survival time, denoted here as t∗. The
main reason for this is the fact that it does not exist a closed form expression for the
standard error of the estimator tˆ∗. A possible solution is to numerically solve the non-linear
equation S0(t∗)− S1(t∗) = 0. In the present paper, we circumvent this issue by proposing a
non-parametric bootstrap method allowing to infer the quantities of interest.
Under the Bayesian framework, prior distributions expressing our initial uncertainty
about the unknown quantities must be specified. We assume that γ (or ξ), ψ, φ (and
β for the alternative formulation of the YP model) are all independent such that: log(γk) ∼
N(µγ, σγ) and log(ξk) ∼ N(µξ, σξ), for k = 1, · · · ,m, ψj ∼ N(µψ, σψ), φj ∼ N(µφ, σφ), for
j = 1, · · · , q and, finally, βl ∼ N(µβ, σβ) for l = 1, · · · , p. The assumption of independence
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is made here to guarantee a fair comparison with the results provided by those models fitted
under the ML framework. The parameters in γ and ξ have a positive support, but we choose
to model them in the log scale due to computational reasons. We emphasize, however, that
other prior distributions for γ and ξ, inducing some sort of dependency among their com-
ponents, for example, can be specified. This is beyond the scope of the present paper, thus
it is left for future work.
3 Simulation Study
In this section, we present a comprehensive Monte Carlo (MC) simulation study to evaluate
the performance of the proposed models in terms of estimation of the regression coefficients
and the crossing survival time point. The analysis is divided in two scenarios:
• Scenario I: a two-sample problem, with focus on the estimation of the regression coef-
ficients and the crossing survival time;
• Scenario II: a general regression setting involving four covariates is investigated, with
focus on the estimation of the regression coefficients. In this case, the original and the
alternative formulations of the YP model are considered.
For each scenario, 1000 MC replications of data sets, with sample size n = 500, were
generated by assuming a Weibull baseline survival function S0(t|α, γ) = exp {−γtα}, with
α = 1.5 and γ = 0.05. Censoring times were originated from an uniform distribution U(0, ν),
with ν chosen in a way that the censoring rate corresponds to approximately 30% of the
observed data. Under the Bayesian framework, for each MC replica, posterior samples of
size 4000 for the quantities of interest were drawn, using the NUTS algorithm (Homan
and Gelman, 2014), after running 4 chains of length 2000, with the first 1000 iteration being
discarded as a warm-up period. All prior distributions were set to have mean 0 and standard
deviation 4. For comparison purposes, for each MC replica, bootstrap estimates for some
target elements were obtained based on 4000 bootstrap samples. All models were fitted
by calling Stan (Stan Development Team, 2018b) from R (R Core Team, 2019) using the
package rstan (Stan Development Team, 2018a).
In order to generate the data sets for Scenario I, the following short-term and long-term
linear predictors were used:
log(λi) = +2.0zi and log(θi) = −1.0zi,
where zi ∼ Bern(0.5). Note that the short and long-term regression coefficients have op-
posite signs, implying that the survival curves will cross. This fact allows us to verify the
performance of the proposed models in the estimation of crossing survival time point.
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Table 2: Monte Carlo simulation study for Scenario I (two-sample). Estimate (est.), average
standard error (se.), standard deviation of the estimates (sde.), relative bias (rb in %) and
coverage probability (nominal level 95%) are presented for the coefficients and the crossing
survival time (t∗).
M1 ML approach Bayesian approach
true est. se. sde. rb cov. est. se. sde. rb cov.
ψ 2.00 2.12 0.31 0.30 6.01 93.90 2.07 0.29 0.29 3.53 94.70
φ -1.00 -1.04 0.15 0.14 -3.75 94.60 -1.03 0.14 0.14 -2.94 94.30
t∗ 47.90 49.22 9.81 11.04 2.76 96.0 48.49 11.20 10.14 1.23 94.0
M2 ML approach Bayesian approach
true est. se. sde. rb cov. est. se. sde. rb cov.
ψ 2.00 2.11 0.31 0.30 5.56 94.30 2.04 0.29 0.29 1.97 94.40
φ -1.00 -1.03 0.15 0.14 -3.30 94.40 -1.01 0.14 0.14 -0.86 95.70
t∗ 47.90 49.39 9.91 11.18 3.11 96.0 49.57 11.62 10.16 3.48 96.0
In the investigations conducted in this section for artificial data, we choose to explore a
measurement accounting for the distance between the reported estimate and the true value
of the parameter. This is called relative bias and it has the following formulation:
rb(κ) = 100 (κˆ− κtrue) / |κtrue|.
In this case consider: κ is a generic parameter, κˆ is the maximum likelihood or posterior
estimate and κtrue is the target true value. The relative bias can be seen as a ratio between
the estimation error and the magnitude of the true value. Negative and positive results
indicate underestimation and overestimation, respectively. The fraction is multiplied by 100
to adjust scale leading to a quantity indicating a percentage representing how big is the error
with respect to the magnitude of the true value. This quantity is often used in the survival
analysis literature.
The variability or uncertainty related to the point estimates are expressed, in this anal-
ysis based on MC replications, through the average standard error (se) and the standard
deviation of the estimates (sde). For a given parameter κ, the average standard error has
the formulation
∑1000
j=1 sej(κ)/1000, where sej(κ) is the standard error (or posterior standard
deviation) obtained for κ in the j-th sample of the MC scheme. On the other hand, the
sde is given by
∑1000
j=1 (κˆj − κ¯)2/999, with κˆj being the estimated κ in the j-th sample and
κ¯ =
∑1000
j=1 κˆj/1000.
Table 2 presents the MC simulation results for Scenario I. As it can be seen, models M1
and M2 have a similar performance in terms of estimation. The results also suggest that the
Bayesian framework provides slightly better estimates than the ML case. Overall, Table 2
shows small relative biases (absolute maximum 6.01%) and coverage probabilities close to
the nominal level of 95%. The coefficient φ tend to be underestimated (rb < 0) and the
remaining quantities are overestimated (rb > 0).
The data generating procedure, associated with Scenario II, considers the short and
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Table 3: Carlo simulation study for Scenario II (general regression). Estimate (est.), average
standard error (se.), standard deviation of the estimates (sde.), relative bias (rb in %) and
coverage probability (nominal level 95%) are presented for the coefficients.
M1 ML approach Bayesian approach
true est. se. sde. rb cov. est. se. sde. rb cov.
ψ1 2.00 2.10 0.23 0.22 4.83 93.10 2.08 0.21 0.23 4.11 91.60
ψ2 -0.50 -0.53 0.10 0.09 -5.34 93.70 -0.53 0.10 0.10 -6.08 93.10
ψ3 1.50 1.56 0.18 0.17 4.01 95.20 1.54 0.17 0.17 2.86 94.70
ψ4 -1.50 -1.55 0.11 0.10 -3.62 92.90 -1.54 0.11 0.11 -2.50 94.00
φ1 -1.00 -1.02 0.20 0.20 -1.69 94.10 -1.03 0.20 0.22 -2.81 93.70
φ2 1.00 1.04 0.15 0.14 4.39 94.00 1.03 0.14 0.16 2.98 94.80
φ3 1.50 1.59 0.31 0.28 5.88 96.40 1.52 0.29 0.29 1.31 95.50
φ4 -1.50 -1.58 0.22 0.20 -5.26 93.70 -1.54 0.21 0.24 -2.57 95.10
M2 ML approach Bayesian approach
true est. se. sde. rb cov. est. se. sde. rb cov.
ψ1 2.00 2.09 0.23 0.22 4.72 92.50 2.05 0.21 0.22 2.40 93.00
ψ2 -0.50 -0.53 0.10 0.09 -5.24 93.60 -0.51 0.09 0.09 -1.73 94.40
ψ3 1.50 1.56 0.18 0.17 3.97 94.90 1.54 0.17 0.17 3.03 95.50
ψ4 -1.50 -1.56 0.11 0.10 -3.73 92.70 -1.55 0.10 0.10 -3.11 93.90
φ1 -1.00 -1.01 0.20 0.20 -0.84 94.10 -0.96 0.19 0.19 4.38 94.30
φ2 1.00 1.04 0.15 0.14 3.64 94.20 1.01 0.14 0.14 0.73 96.00
φ3 1.50 1.57 0.31 0.28 4.89 96.20 1.50 0.29 0.26 0.12 96.30
φ4 -1.50 -1.56 0.21 0.20 -3.74 95.30 -1.40 0.19 0.18 6.80 90.70
M∗1 ML approach Bayesian approach
true est. se. sde. rb cov. est. se. sde. rb cov.
ψ1 2.00 2.08 0.20 0.21 4.11 91.90 2.07 0.19 0.21 3.40 92.20
ψ2 -0.50 -0.52 0.09 0.09 -4.34 93.30 -0.53 0.09 0.09 -5.07 92.80
φ1 -1.00 -1.01 0.19 0.18 -1.43 94.00 -1.03 0.18 0.18 -2.67 93.50
φ2 1.00 1.03 0.13 0.13 3.31 94.40 1.03 0.13 0.13 2.63 94.60
β1 1.50 1.55 0.12 0.12 3.27 93.40 1.52 0.12 0.12 1.56 94.90
β2 -1.50 -1.55 0.08 0.08 -3.19 90.20 -1.53 0.08 0.08 -1.92 94.50
M∗2 ML approach Bayesian approach
true est. se. sde. rb cov. est. se. sde. rb cov.
ψ1 2.00 2.08 0.20 0.21 3.79 92.30 2.00 0.19 0.20 0.08 93.20
ψ2 -0.50 -0.52 0.09 0.09 -4.08 93.30 -0.50 0.09 0.09 0.66 94.50
φ1 -1.00 -1.01 0.18 0.18 -0.70 94.10 -0.93 0.18 0.18 6.66 93.00
φ2 1.00 1.03 0.13 0.13 3.06 94.20 1.02 0.13 0.13 2.28 95.40
β1 1.50 1.55 0.12 0.12 3.08 94.00 1.53 0.12 0.12 2.01 95.30
β2 -1.50 -1.54 0.08 0.08 -2.96 91.00 -1.50 0.08 0.07 0.24 95.80
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long-term linear predictors as follows:
log(λi) = +2.0z1i − 0.5z2i + 1.5z3i − 1.5z4i,
log(θi) = −1.0z1i + 1.0z2i + 1.5z3i − 1.5z4i;
where z1i ∼ Bern(0.5), z2i ∼ N(0, 1), z3i ∼ Bern(0.5) and z4i ∼ N(0, 1), for i = 1, · · · , n.
It is important to highlight the fact that we choose opposite signs for the first two short
and long-term coefficients, which implies that the survival curves will have an intersection
at some intermediate point within the period where the data is generated. In addition, note
that all coefficients are not time dependent. This configuration is chosen to enable a fair
comparison among models based on the original and the alternative formulations of the YP
model previously discussed.
The conclusions from the analysis of Scenario II are similar to those obtained from Sce-
nario I. According to Table 3, all models being examined behave well, regardless of the
approach considered for estimation. Note that again slightly better estimates can be ob-
served for the models fitted under the Bayesian framework. Furthermore, the models M∗1
and M∗2 (alternative formulation) outperform the options M1 and M2 (original formulation)
in terms of relative bias. This result is in fact expected, due to the procedure adopted to
generate the data. In summary, the models M1 and M2 show robustness for estimation,
despite their greater complexity.
When moving from Table 2 to 3, it is possible to detect a small decrease in the overall
performance of the models in terms of relative biases and coverage probability. This result is
expected and can be justified by the fact that the Scenario II (Table 3) is related to modeling
structures having more parameters than those in Scenario I. It seems fair to say that this
decrease is small and it does not compromise the inference in the general regression setting.
4 Real Case Study: Analysis of IPASS Clinical Trial
In this section we present the analysis of the reconstructed IPASS clinical trial data reported
in Argyropoulos and Unruh (2015). Although reconstructed, this data set preserves all fea-
tures exhibited in references with full access to the observations from this clinical trial. The
data base is related to the period of March 2006 to April 2008. The main purpose of the
study is to compare the drug gefitinib against carboplatin/paclitaxel doublet chemotherapy
as first line treatment, in terms of progression free survival (in months), to be applied to
selected non-small-cell lung cancer (NSCLC) patients. According to the protocol established
in the trial, n = 1207 previously untreated individuals in east Asia, who had advanced pul-
monary adenocarcinoma and who were nonsmokers or former light smokers, were randomly
assigned to receive either gefitinib (609 patients) or carboplatin + paclitaxel (608 patients).
The observations indicate 965 occurrences of the event of interest (79.3%), with 516 of them
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(84.9%) corresponding to patients treated with carboplatin+paclitaxel, and 449 of them
(73.7%) being reported for those receiving gefitinib.
The main aim here is to properly analyze the reconstructed IPASS data and estimate the
crossing survival time using the models presented in Section 2. In order to accomplish this
goal, we consider both the likelihood-based and the Bayesian frameworks for the proposals
M1 andM2. We emphasize that the same configurations adopted for the simulation study in
Section 3 are applied in this real application; they include: polynomial’s degree, bootstrap
sample size, prior specifications and MCMC settings.
Table 4: IPASS clinical trial analysis. Coefficients and the crossing survival time (t∗) sum-
marized via point estimate (est.), standard error or standard deviation (se. and sd.), 95%
confidence interval (CI) or 95% credibility interval with highest posterior density (HPD).
ML approach par est. se. lowerCI upperCI
ψ 1.23 0.18 0.87 1.60
M1 φ -1.32 0.08 -1.48 -1.16
t∗ 6.06 0.37 5.30 6.77
ψ 1.22 0.18 0.86 1.59
M2 φ -1.32 0.08 -1.48 -1.15
t∗ 6.08 0.37 5.32 6.77
Bayesian par est. sd. lowerHPD upperHPD
ψ 1.22 0.18 0.89 1.58
M1 φ -1.33 0.09 -1.49 -1.17
t∗ 5.96 0.37 5.19 6.65
ψ 1.19 0.17 0.85 1.52
M2 φ -1.31 0.08 -1.48 -1.16
t∗ 5.94 0.37 5.21 6.65
Table 4 provides the estimates for the short/long-term regression coefficients and the
crossing survival time, along with their respective standard errors/deviations and correspond-
ing interval estimates obtained by the four fitted models. As expected, the short/long-term
regression coefficient estimates have opposite signs, implying that the survival curves asso-
ciated with gefitinib and carboplatin/paclitaxel treatments must cross each other at some
Table 5: IPASS clinical trial analysis. Short and long term hazard ratios summarized via
point estimate (est.), standard error or standard deviation (se. and sd.), 95% confidence
interval (CI) or the 95% credibility interval with highest posterior density (HPD).
ML approach hazard ratio est. se. lowerCI upperCI
M1 gefitinib (short) 3.47 0.64 2.40 4.96
carboplatin/paclitaxel (long) 3.76 0.31 3.17 4.39
M2 gefitinib (short) 3.44 0.64 2.36 4.90
carboplatin/paclitaxel (long) 3.74 0.31 3.17 4.38
Bayesian hazard ratio est. sd. lowerHPD upperHPD
M1 gefitinib (short) 3.43 0.62 2.28 4.62
carboplatin/paclitaxel (long) 3.78 0.32 3.20 4.42
M2 gefitinib (short) 3.34 0.58 2.27 4.51
carboplatin/paclitaxel (long) 3.73 0.30 3.19 4.37
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Figure 1: Estimated survival curves - Kaplan-Meyer (step function) and proposed models
(continuous lines). Consider M1 via ML in panel (a), Bayesian M1 in (b), M2 via ML in (c)
and Bayesian M2 in (d). The horizontal axis represents the follow up time in months. The
estimated crossing time is given by the vertical continuous line (dashed lines indicates the
95% confidence or credibility interval).
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point. In addition, both ψ and φ are statistically significant, indicating that there is a non-
negligible difference between these treatments when comparing the early and late follow up
periods. This is confirmed through the analysis of Table 5, which shows estimated hazard ra-
tios. Note that the hazard of a patient receiving gefitinib at the begining of the treatment is
more than three times the hazard of those treated with carboplatin/paclitaxel. On the other
hand, gefitinib tends to improve in the long run with respect to carboplatin+paclitaxel; the
hazard ratios between patients treated with carboplatin/paclitaxel and gefitinib are larger
than 3.5.
The results displayed in Tables 4 and 5 clearly shows the serious implications of the
misleading use of the Cox PH model when dealing with lifetime data with crossing survival
curves. Our study indicates that the correct clinical practice to be adopted, in terms of
choosing gefitinib or carboplatin/paclitaxel, should take into account the inversion of the
effectiveness of these treatments. Specifically, according to Table 4, patients should start
their treatment receiving carboplatin+paclitaxel, and then switch to gefitinib after 6 months
of follow up.
Figure 1 compares the survival curves obtained through the proposed models and the
usual Kaplan-Meyer estimator for each treatment group. Note that, for all cases, the tra-
jectory of the estimated continuous curves are quite similar to the one exhibited by the step
function. The crossing survival time t∗ is estimated near 6 months (see vertical lines) with
95% interval reasonably small suggesting some precision. The behavior of the curves clearly
indicates that the two treatments experience an inversion along the time, with gefitinib
associated to the lower survival in the short-term or initial phase of the study.
5 Conclusions
This paper introduced an unified approach to fit the YP model by modeling either the
baseline hazard function or the baseline odds function via Bernstein polynomials, under
both the likelihood-based and the Bayesian frameworks. The use of BP to manage the
baseline functions yields some flexibility as no constrains on the shape of these functions
are required. The existence of closed form expressions for the baseline functions determines
simple formulations for the likelihood which, in turn, considerably simplifies all the inferential
procedure. Another central characteristic of the proposed models is their ability to accurately
estimate crossing survival times in a straightforward way. We believe that this feature is
extremely important in many real applications where detecting the crossing survival time
is a key information to establish guidelines for a treatment. This is well illustrated here
through the analysis of the reconstructed IPASS data. In addition, this work also provides
an alternative formulation for the YP model allowing the effects of some covariates to remain
constant over time. This possibility is only mentioned in Yang and Prentice (2005) and, as
far as we know, it has not been addressed in the literature until now.
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We evaluated the performance of the proposed models through a comprehensive Monte
Carlo simulation study considering a two-sample situation, and a general regression scenario
with a set of covariates. To the best of our knowledge, such an extensive simulation study
involving the YP model has never been conducted in the literature. Overall, the proposed
models presented good performance in terms of relative bias and coverage probabilities.
The real illustration related to the IPASS data set revealed that it is a mistake to trust the
analysis based on the usual PH model. This choice induces wrong conclusions which, in turn,
may lead to inappropriate clinical practices in terms of the best treatment for the patients.
As demonstrated in our analysis, in order to increase progression-free survival probabilities,
patients should start their treatment receiving carboplatin/paclitaxel, and then switch to
gefitinib after approximately 6 months of treatment.
Future research includes the development of residual analysis techniques and diagnostic
measures to assess the goodness of fit of the proposed models. In upcoming works we intend
to extend the proposed models to account for interval-censored data and survival data with
cure fraction.
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